Search Results | Cancer Research | American Association for Cancer Research

1-20 of 42

2 3

Sort by

Sort Order Select

Journal Articles

Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies

Yusuke Adachi, Hiroshi Kamiyama, Kenji Ichikawa, Sayo Fukushima, Yoichi Ozawa, Shogo Yamaguchi, Satoshi Goda, Takayuki Kimura, Kotaro Kodama, Masahiro Matsuki, Saori Watanabe Miyano, Akira Yokoi, Yu Kato, Yasuhiro Funahashi

Cancer Res (2022) 82 (2): 292–306.

DOI: https://doi.org/10.1158/0008-5472.CAN-20-2426

Published: 18 January 2022

View article

Includes: Supplementary data

Journal Articles

Abstract 1414: Effect of E7090, an FGFR1-3 selective inhibitor, on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2(-) breast cancer preclinical models

Satoshi Kawano, Sayo Fukushima, Kyoko Nishibata, Ryu Gejima, Yuki Niwa, Yasuhiro Funahashi, Saori Watanabe Miyano

Cancer Res (2021) 81 (13_Supplement): 1414.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1414

Published: 01 July 2021

View article

Journal Articles

E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Cancer Res (2021) 81 (4): 1052–1062.

DOI: https://doi.org/10.1158/0008-5472.CAN-20-0782

Published: 15 February 2021

View article

Includes: Supplementary data

Journal Articles

Abstract 6637: Inhibition of FGFR signaling by lenvatinib activates tumor interferon gamma signaling pathway and potentiates antitumor activity of anti-PD-1 antibody

Yusuke Adachi, Hiroshi Kamiyama, Kenji Ichikawa, Yoichi Ozawa, Sayo Fukushima, Satoshi Goda, Shogo Yamaguchi, Masahiro Matsuki, Saori Watanabe Miyano, Akira Yokoi, Yu Kato, Yasuhiro Funahashi

Cancer Res (2020) 80 (16_Supplement): 6637.

DOI: https://doi.org/10.1158/1538-7445.AM2020-6637

Published: 15 August 2020

View article

Journal Articles

Abstract 1485: E7011, a novel anti-angiogenesis inhibitor targeting Notch4 receptor signal pathway

Cancer Res (2020) 80 (16_Supplement): 1485.

DOI: https://doi.org/10.1158/1538-7445.AM2020-1485

Published: 15 August 2020

View article

Journal Articles

Abstract 2789: Magnetic resonance imaging detects perfusion and diffusion changes in response to a novel microenvironment ameliorator E7130 in a breast cancer model

Masayuki Yamaguchi, Ken Ito, Kazuya Sakaguchi, Yusaku Hori, Yasuhiko Terada, Taro Semba, Yasuhiro Funahashi, Hirofumi Fujii

Cancer Res (2020) 80 (16_Supplement): 2789.

DOI: https://doi.org/10.1158/1538-7445.AM2020-2789

Published: 15 August 2020

View article

Journal Articles

Abstract 2976: Targeting fibroblast growth factor (FGF) signals induced type I IFN regulated response and Immunogenic cell death (ICD) markers in tumor cells with activated FGF signals

Taisuke Hoshi, Yu Kato, Yasuhiro Funahashi

Cancer Res (2020) 80 (16_Supplement): 2976.

DOI: https://doi.org/10.1158/1538-7445.AM2020-2976

Published: 15 August 2020

View article

Journal Articles

Abstract 190: Lenvatinib induced cell death of cultured human hepatocellular carcinoma (HCC) under nutrient-starved condition through inhibition of FGFR signaling pathway

Taisuke Hoshi, Saori Watanabe Miyano, Regina Mikie Kanada Sonobe, Hideki Watanabe, Yuki Seki, Etsuko Ohta, Kenichi Nomoto, Junji Matsui, Yasuhiro Funahashi

Cancer Res (2019) 79 (13_Supplement): 190.

DOI: https://doi.org/10.1158/1538-7445.AM2019-190

Published: 01 July 2019

View article

Journal Articles

Abstract 196: Antitumor activity of lenvatinib against acquired resistance tumor to anti-VEGF therapy in mouse syngeneic tumor models

Kenji Ichikawa, Saori Watanabe Miyano, Yukinori Minoshima, Junji Matsui, Yasuhiro Funahashi

Cancer Res (2019) 79 (13_Supplement): 196.

DOI: https://doi.org/10.1158/1538-7445.AM2019-196

Published: 01 July 2019

View article

Journal Articles

Abstract 2242: Roles of FGFR inhibition on murine RCC cells in combination antitumor activity of lenvatinib with anti-PD1 antibody via regulatingIFN gamma signaling pathway

Yusuke Adachi, Kenji Ichikawa, Yu Kato, Yasuhiro Funahashi

Cancer Res (2019) 79 (13_Supplement): 2242.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2242

Published: 01 July 2019

View article

Journal Articles

Abstract 4089: Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model

Taro Semba, Kimiyo Tabata, Yoichi Ozawa, Saori Watanabe Miyano, Junji Matsui, Yasuhiro Funahashi

Cancer Res (2019) 79 (13_Supplement): 4089.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4089

Published: 01 July 2019

View article

Journal Articles

Abstract 4759: Antitumor activity of eribulin after fulvestrant plus palbociclib treatments in the HR(+) human breast PDx model

Makoto Asano, Takayuki Nakagawa, Taro Semba, Akira Yokoi, Junji Matsui, Yasuhiro Funahashi

Cancer Res (2019) 79 (13_Supplement): 4759.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4759

Published: 01 July 2019

View article

Journal Articles

Abstract 2927: Antitumor and antiangiogenesis activities of E7386, an orally active CBP/β-catenin modulator, as a single agent and in combination with lenvatinib in human HCC xenograft models

Kazuhiko Yamada, Yusaku Hori, Hiroshi Kamiyama, Takayuki Kimura, Yasuhiro Funahashi, Junji Matsui, Yoichi Ozawa

Cancer Res (2018) 78 (13_Supplement): 2927.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2927

Published: 01 July 2018

View article

Journal Articles

Abstract 12: Antitumor activity of lenvatinib in combination with everolimus or an anti-PD1 antibody in preclinical RCC models

Yusuke Adachi, Takayuki Kimura, Masahiro Matsuki, Junji Matsui, Yasuhiro Funahashi

Cancer Res (2018) 78 (13_Supplement): 12.

DOI: https://doi.org/10.1158/1538-7445.AM2018-12

Published: 01 July 2018

View article

Journal Articles

Abstract 5176: E7386, an orally active CBP/beta-catenin modulator, effects tumor microenvironment, resulting to the enhancement of antitumor activity of lenvatinib

Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Yasuhiro Funahashi, Junji Matsui, Tomohiro Matsushima, Takashi Owa

Cancer Res (2017) 77 (13_Supplement): 5176.

DOI: https://doi.org/10.1158/1538-7445.AM2017-5176

Published: 01 July 2017

View article

Journal Articles

Abstract 1805: Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models

Masahiro Matsuki, Yuji Yamamoto, Taisuke Hoshi, Takayuki Kimura, Yasuhiro Funahashi, Junji Matsui

Cancer Res (2017) 77 (13_Supplement): 1805.

DOI: https://doi.org/10.1158/1538-7445.AM2017-1805

Published: 01 July 2017

View article

Journal Articles

Abstract 3264: Lenvatinib in combination with everolimus demonstrated enhanced antiangiogenesis and antitumor activity in human RCC xenograft models

Yusuke Adachi, Masahiro Matsuki, Atsumi Yamaguchi, Yoichi Ozawa, Kiyochi Okamoto, Kaoru Mitsuhashi, Takayuki Kimura, Taisuke Hoshi, Osamu Tohyama, Kenji Tai, Makoto Ogo, Yasuhiro Funahashi, Junji Matsui

Cancer Res (2016) 76 (14_Supplement): 3264.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3264

Published: 15 July 2016

View article

Journal Articles

Abstract 3262: Effects of lenvatinib mesilate in combination with everolimus on VEGF and FGF-driven angiogenesis and tumor growth

Kaoru Mitsuhashi, Takayuki Kimura, Taisuke Hoshi, Osamu Tohyama, Kenji Tai, Makoto Ogo, Masahiro Matsuki, Atsumi Yamaguchi, Yoichi Ozawa, Yusuke Adachi, Kiyoshi Okamoto, Junji Matsui, Yasuhiro Funahashi

Cancer Res (2016) 76 (14_Supplement): 3262.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3262

Published: 15 July 2016

View article

Journal Articles

Abstract 3258: Gene expression and mutation analysis in human osteosarcoma xenograft models associated with combination activity of lenvatinib with etoposide and ifosfamide

Zoltan Dezso, Sergei I. Agoulnik, Crystal MacKenzie, Kaoru Mitsuhashi, Kiyoshi Okamoto, Junji Matsui, Yasuhiro Funahashi

Cancer Res (2016) 76 (14_Supplement): 3258.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3258

Published: 15 July 2016

View article

Journal Articles

Abstract 3266: Antitumor activity of a combination of lenvatinib mesilate, ifosfamide, and etoposide against human pediatric osteosarcoma cell lines

Masahiro Matsuki, Kiyoshi Okamoto, Zoltan Dezso, Sergei I. Agoulnik, Yasuhiro Funahashi, Junji Matsui

Cancer Res (2016) 76 (14_Supplement): 3266.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3266

Published: 15 July 2016

View article

2 3

NARROW

Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies

Abstract 1414: Effect of E7090, an FGFR1-3 selective inhibitor, on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2(-) breast cancer preclinical models

E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Abstract 6637: Inhibition of FGFR signaling by lenvatinib activates tumor interferon gamma signaling pathway and potentiates antitumor activity of anti-PD-1 antibody

Abstract 1485: E7011, a novel anti-angiogenesis inhibitor targeting Notch4 receptor signal pathway

Abstract 2789: Magnetic resonance imaging detects perfusion and diffusion changes in response to a novel microenvironment ameliorator E7130 in a breast cancer model

Abstract 2976: Targeting fibroblast growth factor (FGF) signals induced type I IFN regulated response and Immunogenic cell death (ICD) markers in tumor cells with activated FGF signals

Abstract 190: Lenvatinib induced cell death of cultured human hepatocellular carcinoma (HCC) under nutrient-starved condition through inhibition of FGFR signaling pathway

Abstract 196: Antitumor activity of lenvatinib against acquired resistance tumor to anti-VEGF therapy in mouse syngeneic tumor models

Abstract 2242: Roles of FGFR inhibition on murine RCC cells in combination antitumor activity of lenvatinib with anti-PD1 antibody via regulatingIFN gamma signaling pathway

Abstract 4089: Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model

Abstract 4759: Antitumor activity of eribulin after fulvestrant plus palbociclib treatments in the HR(+) human breast PDx model

Abstract 2927: Antitumor and antiangiogenesis activities of E7386, an orally active CBP/β-catenin modulator, as a single agent and in combination with lenvatinib in human HCC xenograft models

Abstract 12: Antitumor activity of lenvatinib in combination with everolimus or an anti-PD1 antibody in preclinical RCC models

Abstract 5176: E7386, an orally active CBP/beta-catenin modulator, effects tumor microenvironment, resulting to the enhancement of antitumor activity of lenvatinib

Abstract 1805: Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models

Abstract 3264: Lenvatinib in combination with everolimus demonstrated enhanced antiangiogenesis and antitumor activity in human RCC xenograft models

Abstract 3262: Effects of lenvatinib mesilate in combination with everolimus on VEGF and FGF-driven angiogenesis and tumor growth

Abstract 3258: Gene expression and mutation analysis in human osteosarcoma xenograft models associated with combination activity of lenvatinib with etoposide and ifosfamide

Abstract 3266: Antitumor activity of a combination of lenvatinib mesilate, ifosfamide, and etoposide against human pediatric osteosarcoma cell lines

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only